Simulation of psychosis by continuous delivery of phencyclidine from controlled-release polymer implants

被引:18
作者
Schroeder, U
Schroeder, H
Darius, J
Grecksch, G
Sabel, BA
机构
[1] Univ Magdeburg, Inst Med Psychol, Fac Med, D-39120 Magdeburg, Germany
[2] Univ Magdeburg, Inst Pharmacol & Toxicol, Fac Med, D-39120 Magdeburg, Germany
[3] Univ Magdeburg, Inst Clin Pharmacol, Fac Med, D-39120 Magdeburg, Germany
关键词
controlled-release polymer; hippocampus; latent inhibition; pharmacokinetics; schizophrenia; H-3; TCP-binding;
D O I
10.1016/S0166-4328(98)00027-8
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
To simulate psychosis in rats we have developed a method for the continuous delivery of phencyclidine (PCP) using implantable controlled-release polymers. PCP polymer implants produced deficits in latent inhibition which do not occur after repeated bolus injections. PCP implanted rats were also devoid of any anxiogenic signs, motoric hyperactivity and learning acquisition which can be seen in rats receiving daily bolus injections of a comparable PCP dose. This behavioral double-dissociation of the two modes of PCP application was accompanied by respective neurochemical changes. PCP binding sites were reduced in both striatum and hippocampus, but in the hippocampus, loss of PCP binding sites was more severe following pulsatile PCP administration. Morphological assessment revealed a significant shrinkage of the CA3 region in hippocampus in both groups. Pharmacokinetic analysis showed that the maximum PCP concentration in the brain after bolus injections was 10-fold above the PCP implants. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:59 / 68
页数:10
相关论文
共 45 条
[1]  
ANSCOMBE F, 1987, SCHIZOPHRENIA B, V2, P241
[2]  
BALSTER RL, 1987, PSYCHOPHARMACOLOGY 3, P1573
[3]   RECENT ADVANCES IN THE NEUROPATHOLOGY OF SCHIZOPHRENIA [J].
BOGERTS, B .
SCHIZOPHRENIA BULLETIN, 1993, 19 (02) :431-445
[4]   INTERACTIONS BETWEEN GLUTAMATERGIC AND MONOAMINERGIC SYSTEMS WITHIN THE BASAL GANGLIA - IMPLICATIONS FOR SCHIZOPHRENIA AND PARKINSONS-DISEASE [J].
CARLSSON, M ;
CARLSSON, A .
TRENDS IN NEUROSCIENCES, 1990, 13 (07) :272-276
[5]   The glutamatergic dysfunction hypothesis for schizophrenia [J].
Coyle, JT .
HARVARD REVIEW OF PSYCHIATRY, 1996, 3 (05) :241-253
[6]   CONTROLLED RELEASE OF DOPAMINE FROM A POLYMERIC BRAIN IMPLANT - INVIVO CHARACTERIZATION [J].
DURING, MJ ;
FREESE, A ;
SABEL, BA ;
SALTZMAN, WM ;
DEUTCH, A ;
ROTH, RH ;
LANGER, R .
ANNALS OF NEUROLOGY, 1989, 25 (04) :351-356
[7]   COMPETITIVE AND NONCOMPETITIVE NMDA ANTAGONISTS INDUCE SIMILAR LIMBIC DEGENERATION [J].
ELLISON, G .
NEUROREPORT, 1994, 5 (18) :2688-2692
[8]   DISSIMILAR PATTERNS OF DEGENERATION IN BRAIN FOLLOWING 4 DIFFERENT ADDICTIVE STIMULANTS [J].
ELLISON, G ;
SWITZER, RC .
NEUROREPORT, 1993, 5 (01) :17-20
[9]   THE N-METHYL-D-ASPARTATE ANTAGONISTS PHENCYCLIDINE, KETAMINE AND DIZOCILPINE AS BOTH BEHAVIORAL AND ANATOMICAL MODELS OF THE DEMENTIAS [J].
ELLISON, G .
BRAIN RESEARCH REVIEWS, 1995, 20 (02) :250-267
[10]   Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: Potential relevance to schizophrenia? [J].
Farber, NB ;
Wozniak, DF ;
Price, MT ;
Labruyere, J ;
Huss, J ;
Peter, HS ;
Olney, JW .
BIOLOGICAL PSYCHIATRY, 1995, 38 (12) :788-796